NASD · Healthcare · Biotechnology · USA
SELLAS Life Sciences Group Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing cancer therapeutics. Its lead product is galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen in blood and solid cancers, currently in clinical testing for acute myeloid leukemia. The company also develops SLS009, a selective CDK9 inhibitor in clinical trials for hematologic and solid tumors.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the SELLAS Life Sciences Group Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on SLS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-20 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.